1. Home
  2. FENG vs JSPR Comparison

FENG vs JSPR Comparison

Compare FENG & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phoenix New Media Limited

FENG

Phoenix New Media Limited

HOLD

Current Price

$1.49

Market Cap

18.0M

Sector

Industrials

ML Signal

HOLD

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.78

Market Cap

14.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FENG
JSPR
Founded
1998
2018
Country
China
United States
Employees
N/A
22
Industry
Broadcasting
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.0M
14.9M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
FENG
JSPR
Price
$1.49
$0.78
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
9.3K
732.4K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$0.32
52 Week High
$3.65
$3.31

Technical Indicators

Market Signals
Indicator
FENG
JSPR
Relative Strength Index (RSI) 40.33 64.82
Support Level N/A $0.79
Resistance Level $1.80 $1.06
Average True Range (ATR) 0.04 0.12
MACD -0.00 0.05
Stochastic Oscillator 9.37 65.60

Price Performance

Historical Comparison
FENG
JSPR

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: